176 related articles for article (PubMed ID: 25651948)
1. The Use of Anti-CD40 mAb in Cancer.
Remer M; White A; Glennie M; Al-Shamkhani A; Johnson P
Curr Top Microbiol Immunol; 2017; 405():165-207. PubMed ID: 25651948
[TBL] [Abstract][Full Text] [Related]
2. Role of crosslinking for agonistic CD40 monoclonal antibodies as immune therapy of cancer.
Richman LP; Vonderheide RH
Cancer Immunol Res; 2014 Jan; 2(1):19-26. PubMed ID: 24416732
[TBL] [Abstract][Full Text] [Related]
3. Agonistic CD40 antibodies and cancer therapy.
Vonderheide RH; Glennie MJ
Clin Cancer Res; 2013 Mar; 19(5):1035-43. PubMed ID: 23460534
[TBL] [Abstract][Full Text] [Related]
4. Anti-CD 40 monoclonal antibody.
Geldart T; Illidge T
Leuk Lymphoma; 2005 Aug; 46(8):1105-13. PubMed ID: 16085550
[TBL] [Abstract][Full Text] [Related]
5. Fcγ receptor dependency of agonistic CD40 antibody in lymphoma therapy can be overcome through antibody multimerization.
White AL; Dou L; Chan HT; Field VL; Mockridge CI; Moss K; Williams EL; Booth SG; French RR; Potter EA; Butts C; Al-Shamkhani A; Cragg MS; Verbeek JS; Johnson PW; Glennie MJ; Beers SA
J Immunol; 2014 Aug; 193(4):1828-35. PubMed ID: 25024386
[TBL] [Abstract][Full Text] [Related]
6. CD40 Agonist Antibodies in Cancer Immunotherapy.
Vonderheide RH
Annu Rev Med; 2020 Jan; 71():47-58. PubMed ID: 31412220
[TBL] [Abstract][Full Text] [Related]
7. CD40 activation as potential tool in malignant neoplasms.
Ottaiano A; Pisano C; De Chiara A; Ascierto PA; Botti G; Barletta E; Apice G; Gridelli C; Iaffaioli VR
Tumori; 2002; 88(5):361-6. PubMed ID: 12487551
[TBL] [Abstract][Full Text] [Related]
8. T-cell-independent antitumor effects of CD40 ligation.
Rakhmilevich AL; Alderson KL; Sondel PM
Int Rev Immunol; 2012 Aug; 31(4):267-78. PubMed ID: 22804571
[TBL] [Abstract][Full Text] [Related]
9. CD40 ligation for immunotherapy of solid tumours.
Todryk SM; Tutt AL; Green MH; Smallwood JA; Halanek N; Dalgleish AG; Glennie MJ
J Immunol Methods; 2001 Feb; 248(1-2):139-47. PubMed ID: 11223075
[TBL] [Abstract][Full Text] [Related]
10. Inhibitory Fcγ receptor engagement drives adjuvant and anti-tumor activities of agonistic CD40 antibodies.
Li F; Ravetch JV
Science; 2011 Aug; 333(6045):1030-4. PubMed ID: 21852502
[TBL] [Abstract][Full Text] [Related]
11. Agonistic CD40 mAb-Driven IL12 Reverses Resistance to Anti-PD1 in a T-cell-Rich Tumor.
Ngiow SF; Young A; Blake SJ; Hill GR; Yagita H; Teng MW; Korman AJ; Smyth MJ
Cancer Res; 2016 Nov; 76(21):6266-6277. PubMed ID: 27634762
[TBL] [Abstract][Full Text] [Related]
12. Anti-CD40 monoclonal antibody therapy in combination with irradiation results in a CD8 T-cell-dependent immunity to B-cell lymphoma.
Honeychurch J; Glennie MJ; Johnson PW; Illidge TM
Blood; 2003 Aug; 102(4):1449-57. PubMed ID: 12714523
[TBL] [Abstract][Full Text] [Related]
13. Next Generation CD40 Agonistic Antibodies for Cancer Immunotherapy.
Salomon R; Dahan R
Front Immunol; 2022; 13():940674. PubMed ID: 35911742
[TBL] [Abstract][Full Text] [Related]
14. Toxicity of an Fc-engineered anti-CD40 antibody is abrogated by intratumoral injection and results in durable antitumor immunity.
Knorr DA; Dahan R; Ravetch JV
Proc Natl Acad Sci U S A; 2018 Oct; 115(43):11048-11053. PubMed ID: 30297432
[TBL] [Abstract][Full Text] [Related]
15. Fc-engineered anti-CD40 antibody enhances multiple effector functions and exhibits potent in vitro and in vivo antitumor activity against hematologic malignancies.
Horton HM; Bernett MJ; Peipp M; Pong E; Karki S; Chu SY; Richards JO; Chen H; Repp R; Desjarlais JR; Zhukovsky EA
Blood; 2010 Oct; 116(16):3004-12. PubMed ID: 20616215
[TBL] [Abstract][Full Text] [Related]
16. Monoclonal antibodies: versatile platforms for cancer immunotherapy.
Weiner LM; Surana R; Wang S
Nat Rev Immunol; 2010 May; 10(5):317-27. PubMed ID: 20414205
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic Activity of Agonistic, Human Anti-CD40 Monoclonal Antibodies Requires Selective FcγR Engagement.
Dahan R; Barnhart BC; Li F; Yamniuk AP; Korman AJ; Ravetch JV
Cancer Cell; 2016 Jun; 29(6):820-831. PubMed ID: 27265505
[TBL] [Abstract][Full Text] [Related]
18. Macrophage-dependent nitric oxide expression regulates tumor cell detachment and metastasis after IL-2/anti-CD40 immunotherapy.
Weiss JM; Ridnour LA; Back T; Hussain SP; He P; Maciag AE; Keefer LK; Murphy WJ; Harris CC; Wink DA; Wiltrout RH
J Exp Med; 2010 Oct; 207(11):2455-67. PubMed ID: 20921282
[TBL] [Abstract][Full Text] [Related]
19. An Fcγ receptor-dependent mechanism drives antibody-mediated target-receptor signaling in cancer cells.
Wilson NS; Yang B; Yang A; Loeser S; Marsters S; Lawrence D; Li Y; Pitti R; Totpal K; Yee S; Ross S; Vernes JM; Lu Y; Adams C; Offringa R; Kelley B; Hymowitz S; Daniel D; Meng G; Ashkenazi A
Cancer Cell; 2011 Jan; 19(1):101-13. PubMed ID: 21251615
[TBL] [Abstract][Full Text] [Related]
20. Design of CD40 agonists and their use in growing B cells for cancer immunotherapy.
Kornbluth RS; Stempniak M; Stone GW
Int Rev Immunol; 2012 Aug; 31(4):279-88. PubMed ID: 22804572
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
